When The Trial Site Is A Living Room: Pharma Explores Virtual Research Options
Executive Summary
One day in the future, clinical studies may routinely be carried out in the virtual world, with patients mostly staying put at home instead of traveling to trial sites. For now, sponsors are experimenting with new models for drug development and taking it one step at a time.
You may also be interested in...
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
Keeping Track: Mylan Wins First US FDA Approval For Neulasta Biosimilar, But Lands A CRL For Insulin Glargine; Genentech Nabs Broad Full Approval For Venclexta, PV Indication For Rituxan
The latest drug development news and highlights from our US FDA Performance Tracker.
Interview: Novartis Takes Virtual Route To Transform Clinical Trial Paradigm
Jake LaPorte, head of digital development at the Swiss major, has told Scrip that the expansion of Novartis' collaboration with Science 37 will move decentralized trials away from the pilot stage into a scaleable model that will have a genuine impact on the way R&D is conducted in the future.
Need a specific report? 1000+ reports available
Buy Reports